BR112022021445A2 - Métodos e composições para tratar condições inflamatórias associadas com doença infecciosa - Google Patents
Métodos e composições para tratar condições inflamatórias associadas com doença infecciosaInfo
- Publication number
- BR112022021445A2 BR112022021445A2 BR112022021445A BR112022021445A BR112022021445A2 BR 112022021445 A2 BR112022021445 A2 BR 112022021445A2 BR 112022021445 A BR112022021445 A BR 112022021445A BR 112022021445 A BR112022021445 A BR 112022021445A BR 112022021445 A2 BR112022021445 A2 BR 112022021445A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- conditions associated
- methods
- infectious disease
- inflammatory conditions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/366—Thrombomodulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Endocrinology (AREA)
Abstract
MÉTODOS E COMPOSIÇÕES PARA TRATAR CONDIÇÕES INFLAMATÓRIAS ASSOCIADAS COM DOENÇA INFECCIOSA. São divulgadas neste documento composições compreendendo uma preparação de células-tronco mesenquimais (MSC) e uma ou mais biomoléculas e o uso das referidas composições para o tratamento ou uma infecção microbiana ou os sintomas ou condições patológicas secundárias associadas à referida infecção.112022021445-6
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063013865P | 2020-04-22 | 2020-04-22 | |
US202063198706P | 2020-11-06 | 2020-11-06 | |
PCT/US2021/028686 WO2021216903A1 (en) | 2020-04-22 | 2021-04-22 | Methods and compositions for treating inflammatory conditions associated with infectious disease |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022021445A2 true BR112022021445A2 (pt) | 2023-01-10 |
Family
ID=78270105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022021445A BR112022021445A2 (pt) | 2020-04-22 | 2021-04-22 | Métodos e composições para tratar condições inflamatórias associadas com doença infecciosa |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230159932A1 (pt) |
EP (1) | EP4138867A4 (pt) |
JP (1) | JP2023523588A (pt) |
KR (1) | KR20230004709A (pt) |
CN (1) | CN115843253A (pt) |
AU (1) | AU2021261384A1 (pt) |
BR (1) | BR112022021445A2 (pt) |
CA (1) | CA3180973A1 (pt) |
IL (1) | IL297563A (pt) |
MX (1) | MX2022013301A (pt) |
WO (1) | WO2021216903A1 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102317052B1 (ko) * | 2020-05-04 | 2021-10-25 | 주식회사 티에스셀바이오 | 태반 유래의 세포외 소포의 항염증 항바이러스 효과 조성물 |
CN113789333B (zh) * | 2021-09-07 | 2023-07-14 | 中国人民解放军军事科学院军事医学研究院 | Chi3l1在调控hUC-MSCs抑制Th17分化介导的免疫调节作用上的应用 |
CN114469996B (zh) * | 2021-12-23 | 2023-10-20 | 中国医学科学院医学生物学研究所 | 一种包含miR-135b-5p的外泌体及在抗轮状病毒感染中的应用 |
US20230313191A1 (en) * | 2022-03-29 | 2023-10-05 | Direct Biologics Llc | Rna comprising secretomes and methods of their use |
CN115478117A (zh) * | 2022-05-11 | 2022-12-16 | 江苏命码生物科技有限公司 | 一种用于早期预警新型冠状病毒中重型、危重型病例的试剂盒 |
US11878036B2 (en) | 2022-05-25 | 2024-01-23 | Neuvian LLC | Vaginal care compositions and methods of improving vaginal health |
JP7406059B1 (ja) | 2022-10-20 | 2023-12-27 | 防衛装備庁長官 | 急性ストレス評価用データの生成方法 |
CN116656699B (zh) * | 2023-05-16 | 2024-05-31 | 南京农业大学 | SESN2和chi-miR-130b-3p在调节由玉米赤霉烯酮诱导的颗粒细胞凋亡中的应用 |
CN116515995B (zh) * | 2023-06-29 | 2023-09-19 | 迈杰转化医学研究(苏州)有限公司 | 一种检测噬血细胞性淋巴组织细胞增生症的血清microRNA标志物及其应用 |
CN116875550B (zh) * | 2023-09-08 | 2023-12-26 | 天津市肿瘤医院(天津医科大学肿瘤医院) | 一种FABP4+C1q+巨噬细胞及其制备方法和用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190000886A1 (en) * | 2016-03-16 | 2019-01-03 | Duncan ROSS | Method of treatment of osteochondral defects |
EA202091219A1 (ru) * | 2017-11-16 | 2020-08-18 | Селулэрити, Инк. | Культивирование плаценты с целью выделения экзосом |
CN112334190B (zh) * | 2018-04-30 | 2024-09-20 | 儿童医学中心公司 | 间充质基质细胞外排体及其用途 |
IT201900003639A1 (it) * | 2019-03-13 | 2020-09-13 | Evobiotech S R L | Composizioni di vescicole extracellulari (EV) derivate da piante e loro usi |
-
2021
- 2021-04-22 IL IL297563A patent/IL297563A/en unknown
- 2021-04-22 AU AU2021261384A patent/AU2021261384A1/en active Pending
- 2021-04-22 BR BR112022021445A patent/BR112022021445A2/pt unknown
- 2021-04-22 WO PCT/US2021/028686 patent/WO2021216903A1/en unknown
- 2021-04-22 US US17/920,997 patent/US20230159932A1/en active Pending
- 2021-04-22 MX MX2022013301A patent/MX2022013301A/es unknown
- 2021-04-22 CN CN202180035727.1A patent/CN115843253A/zh active Pending
- 2021-04-22 KR KR1020227040483A patent/KR20230004709A/ko active Search and Examination
- 2021-04-22 EP EP21793396.9A patent/EP4138867A4/en active Pending
- 2021-04-22 JP JP2022564314A patent/JP2023523588A/ja active Pending
- 2021-04-22 CA CA3180973A patent/CA3180973A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20230004709A (ko) | 2023-01-06 |
AU2021261384A1 (en) | 2022-12-22 |
JP2023523588A (ja) | 2023-06-06 |
CA3180973A1 (en) | 2021-10-28 |
EP4138867A4 (en) | 2024-05-01 |
WO2021216903A1 (en) | 2021-10-28 |
CN115843253A (zh) | 2023-03-24 |
EP4138867A1 (en) | 2023-03-01 |
MX2022013301A (es) | 2023-02-14 |
IL297563A (en) | 2022-12-01 |
US20230159932A1 (en) | 2023-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022021445A2 (pt) | Métodos e composições para tratar condições inflamatórias associadas com doença infecciosa | |
BR112021023814A2 (pt) | Inibidores de proteases de cisteína e métodos de uso das mesmas | |
BR112022010349A2 (pt) | Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma | |
BR112021022666A2 (pt) | Frações de separação e seus métodos e uso | |
BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
BR112018075288A2 (pt) | métodos para diagnóstico de infecções bacterianas e virais | |
BR112022003335A2 (pt) | Conjugados de il-2 e métodos de uso para tratar doenças autoimunes | |
BR112015019066A2 (pt) | Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos | |
BR112019009106A2 (pt) | método para aumentar os níveis de secreção sem afetar as funções biológicas de il-2 de humano recombinante e suas proteínas mutantes derivadas, proteínas obtidas, e, usos do método e das proteínas obtidas | |
BR112022002837A2 (pt) | Anticorpo anti-vd1 ou fragmento do mesmo, anticorpo multiespecífico isolado ou fragmento do mesmo, anticorpo humano e anticorpo multiespecífico isolado humano ou fragmento do mesmo | |
BR112021017738A8 (pt) | Células-tronco mesenquimais imunomoduladoras | |
BR112017024891A2 (pt) | conjunto de anel de turbina | |
AR092188A1 (es) | ANTICUERPOS HUMANOS PARA GFRa3 Y METODOS PARA SU USO | |
BR112012019881A2 (pt) | proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23 | |
BR112015017307A2 (pt) | composições de espécies com baixa acidez e métodos para produção e uso das mesmas | |
BR112017011067A2 (pt) | cepas e métodos para a partição de energia em ruminantes | |
BR112022015969A2 (pt) | Composições e métodos para enxerto de células editadas de base | |
BR112021023048A2 (pt) | Moléculas de ligação a cd19 e usos das mesmas | |
BR112022001359A2 (pt) | Método e composição para anticorpos anti-cd73 e variantes | |
BR112022016456A2 (pt) | Formulações de anticorpos anti-tslp humanos e métodos de uso dos mesmos | |
BR112023009172A2 (pt) | Métodos, sistemas e kits para tratamento de doenças inflamatórias direcionados à tl1a | |
BR112021025116A2 (pt) | Células linfocíticas ativadas e métodos de uso das mesmas para tratar câncer e condições infecciosas | |
BR112021019120A2 (pt) | Células t específicas para antígenos de múltiplos vírus respiratórios e métodos de produção e uso das mesmas terapeuticamente | |
UY31325A1 (es) | Composiciones y métodos para tratar enfermedades y trastornos inmunologicos e inflamatorios | |
CL2021002837A1 (es) | Formas sólidas de un inhibidor de glyt1 |